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Background: While single growth factor has limitation to induce optimal neovascularization, platelet-rich plasma (PRP)
is an autologous reserver of various growth factors. However, little is known about the mechanism of PRP-related
neovascularization.The objective of this investigation was to characterize the angiogenic and growth factor content of
PRP and to determine, in vitro, its effect on endothelial cell proliferation. Additionally, this experiment sought to
determine the effectiveness of different compositions of PRP (solution versus sustained release) on perfusion and
neovascularization in a murine model of hind limb ischemia.
Methods: Different growth factors were measured by enzyme-linked immunosorbent assay (ELISA). In vivo study, we used
gelatin hydrogel as a sustained release carrier for growth factors in PRP. We induced hind limb ischemia by excising right
femoral artery in wild type C57BL6 mice. After surgery, mice were randomly assigned to four experimental groups; control
(C), 100 L of sustained release form of platelet-poor plasma (PPP), 100 L of solution form of PRP (PRP-sol), 100 L of
sustained release formof PRP (PRP-sr); each formulationwas administered via an intramuscular injection to the ischemic hind
limb. Endpoint evaluations were blood perfusion by laser Doppler perfusion image, vascular density by anti Von Willebrand
factor (vWF), and mature vessel density by anti smooth muscle actin (SMA) antibody. Green fluorescent protein (GFP)
transgenic mice were generated by transplantation of bone marrow derivedmononuclear cells to wild type C57BL6mice, and
finally CD34 cell in the ischemic site of transgenic mice was detected by staining with anti-CD34 antibody.
Results: In vitro study showed that PRP containing different growth factors induces endothelial cell proliferation and capillary
tube formation. In vivo study demonstrated that sustained release of PRP increased perfusion of ischemic tissue as measured
by laser Doppler perfusion imaging (LDPI) (57  12, 56  9, 72  7, 98  4 for groups C, PPP, PRP-sol, and PRP-sr,
respectively; P< .05); capillary density (151 16, 158 12, 189 39, 276 39 for groups C, PPP, PRP-sol, and PRP-sr,
respectively, P < .05) and mature vessel density (28  2, 31  3, 52  10, 85  13 for groups C, PPP, PRP-sol, and
PRP-sr, respectively, P < .05) . Sustained release PRP also increases CD34 cells in the ischemic site of transgenic mice
(6  3 vs 18  5/mm2 for groups control and PRP-sr respectively, P < .05).
Conclusion: Sustained release of PRP containing potent angiogenic growth factors restores blood perfusion presumably
by stimulating angiogenesis, arteriogenesis, as well as vasculogenesis in the mouse hind limb ischemia. (J Vasc Surg
2009;50:870-9.)
Clinical relevance: PRP is a natural reserver of various growth factors that can be collected autologously and is cost
effective. Thus for clinical use, no special considerations concerning antibody formation and infection risk are needed.
Some clinical devices to automatically prepare PRP are available at present. PRP are consistently being used clinically in
the department of orthopedics and plastic surgery (oral, maxillary facial) for a long time. On the basis of research
evidence, some publications have reported positive results in either bone or soft tissue healing. However, some research
concludes that there is no or little benefit from PRP. This is likely due to faster degradation of growth factors in PRP since
some authors suggest using sustained release form of PRP to deliver optimal effect of PRP. Gelatin hydrogel is also being
used clinically as a slow, sustained release of carrier for growth factors in our center recently.Therapeutic angiogenesis remains an attractive treat-
ment modality for critical limb ischemia (CLI). However,
clinical trials of single and solution form of pro- angiogenic
agents have little to no practical utility in patients with such
a disorder. Therefore, there remains a clear need for better
interventions with which to induce therapeutic angiogene-
sis.1,2 The establishment of stable and functional blood
vessel networks however is a complex process that requires
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870several angiogenic factors to stimulate vessel sprouting and
remodeling of the primitive vascular network.3-5
Neovascularization involves multiple complex events
such as the sprouting of pre-existing resident endothelial
cells (angiogenesis), maturation and enlargement of size of
the preexisting small vessels through vascular remodeling
(arteriogenesis), and the recruitment of bone marrow de-
rived endothelial progenitor cells (vasculogenesis).6
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(PRP), a limited volume of plasma enriched in platelets, is
an attracting attention as a safe and cost-effective source of
various growth factors.7,8 PRP, by containing these various
cytokines, plays an important role in regenerating damaged
tissue.9-11 However, little is known about the mechanism
of PRP-related regeneration of damaged tissue. In this
present study, we used gelatin hydrogel as sustained release
carrier for growth factors in PRP.12
The objective of this investigation was to characterize
the angiogenic and growth factor content of PRP and to
determine, in vitro, its effect on endothelial cell prolifera-
tion. Additionally, this experiment sought to determine the
effectiveness of different compositions of PRP (solution vs
sustained release) on perfusion and neovascularization in a
murine model of hind limb ischemia.
METHODS
Experimental animals. Six-week old male C57BL/6
mice and six-week old transgenic mice expressing green
fluorescent protein (GFP; Jackson Laboratory, Bar Harbor,
Me) were purchased from Japan SLC (Shizuoka, Japan)
and Jackson Laboratory respectively. Kyoto University An-
imal Experiment Committee approved the experiment pro-
tocol. Animals were cared for in compliance with the Guide
for the Care and Use of Laboratory Animals, Institute of
Laboratory Animal Resources, Commission on Life Sci-
ences, National Research Council.
Preparation of PRP and platelet-poor plasma
(PPP). Peripheral blood (10 mL) was collected from
C57BL/6 mice using anticoagulant, citrate-phosphate-
dextrose solution. Collected blood was centrifuged at 2400
rpm for 10 minutes at 200C and the supernatant (plasma)
including the buffy coat and 0.5 mL below buffy coat was
decanted to the other tube and red blood cells (RBCs) and
white blood cells (WBCs) were discarded. Secondary cen-
trifugation was performed at 3600 rpm for 10 minutes at
200C. The clear supernatant (plasma) was decanted off
until 0.5 mL was left and the middle portion of supernatant
(plasma) was taken as PPP. Finally, remaining supernatant
including buffy coat and 0.5mL below buffy coat was taken
as PRP and stored at 800C for various evaluations. The
quantification of platelets in PRP was done from Falco
Laboratory, Kyoto, Japan.
Preparation of gelatin hydrogel microspheres con-
taining PRP. Platelet-rich plasma contains different cyto-
kines but these cytokines are effective for a very short time,
having faster degradation. Our previous studies have shown
that when platelets in PRP are activated with gelatin mol-
ecules during the process of PRP impregnation, growth
factors are released from the PRP. The growth factors
secreted are immobilized in the hydrogel through physico-
chemical interaction with gelatin molecules. The immobi-
lized growth factors are released from the hydrogel as a
result of hydrogel degradation.13,14 We have also devel-
oped sustained release form for the many growth factors
and have shown that sustained release of these growth
factors incorporated in gelatin hydrogel microspheres effec-tively restores revascularization in different models of car-
diovascular disease.15-17 Thus, we have used gelatin hydro-
gel as a carrier for the growth factors in the PRP.
Gelatin hydrogel microspheres incorporating PRP
were prepared as described previously.13-17 Briefly, gelatin
with an isoelectric point (IEP) of 4.9 was isolated from
bovine bone collegen by an alkaline process usingCa(OH)2
(Nitta Gelatin, Osaka, Japan). Gelatin microsphere was
prepared through 1) cross linking of gelatin in aqueous
solution dispersed in an oil phase and 2) cross linking of
gelatin microsphere with glutaraldehyde. Microsphere di-
ameter was measured for at least 100 microspheres by
viewing with a light microscope to calculate their volume.
The average diameter of the freeze-dried microspheres was
26 m.
PRP and PPP were incorporated into the gelatin mi-
crospheres by dropping 100 L of PRP or 100 L of PPP
solution into 10 mg of freeze-dried gelatin microspheres
respectively, which were then left in incubator for 1 hour at
370 C. The solution (100 L) was completely absorbed
into the microspheres during swelling, since the solution
volume was less than that of theoretically required for the
equilibrated swelling of microspheres. At use, the PRP
containing gelatin hydrogel microspheres were dispersed in
100L of phosphate buffered saline (PBS), aspirated into 1
mL syringe attached with a 27-gauze needle (Terumo,
Tokyo, Japan), and applied by single intra-muscular injec-
tion to the ischemic site.
Measurement of different growth factors using En-
zyme Linked Immunosorbant Assay (ELISA). Diffe-
rent growth factors such as stromal cell derived factor 1-
(SDF-1), platelet-derived growth factor BB (PDGF-BB),
vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), and insulin like growth factor-1
(IGF-1) concentration in PRP and PPP were quantified
using ELISA methods (R&D Center, Tokyo, Japan). The
analyses were then performed as instructed by manufac-
turer. Briefly, sample and standards were added to 96
growth factor antibody coated well plates. After incuba-
tion, and removal of unbound substances, an enzymes
coupled secondary antibody was added. This step was fol-
lowed by a further washing step and incubation with a
substrate. The color reaction was stopped and optical den-
sity measured at the appropriate wavelength.
Endothelial cell proliferation assay. Endothelial cell
proliferation assay was performed as described previously18
and also briefly described in Appendix (online only).
Tube formation assay. Capillary tube formation assay
was done as described previously18 and also briefly de-
scribed in Appendix (online only).
Mouse ischemic hind limb model. Hind limb isch-
emia was performed in C57BL/6 mice as described previ-
ously15,16 and also briefly described in Appendix (online
only).
Study groups. After surgery, the mice were randomly
assigned to four experimental groups (n 10, each group)
and treated for four weeks: 10 mg gelatin hydrogel micro-
spheres only (group C); sustained release form of PPP (100
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pheres, group PPP), 100 L solution form of PRP (group
PRP-sol), sustained release form of PRP (100 L PRP/10
mg gelatin hydrogel micropheres, group PRP-sr), single
intramuscular injection to the ischemic site.
Measurement of hind limb blood perfusion. Hind
limb blood perfusion was scanned using a laser Doppler
perfusion image (LDPI) analyzer (Moor Instruments,
Devon, UK) as previously described15,16 and also briefly
described in Appendix (online only).
Immunohistological analysis. Immunohistological
study was done as previously described15,16 and also briefly
described in Appendix (online only).
Generation of GFP chimeric mice. The femoral
and tibial bone marrow of 6 weeks old transgenic mice
expressing green fluorescent protein (GFP; Jackson Labo-
ratory) were isolated by flushing with PBS (pH 7.2).
Mononuclear leucocytes were isolated from total bone
marrow cells by percoll mediated single density gradient
centrifugation. Then the six week old male wild-type
(C57BL/6) recipient mice were lethally irradiated with a
total dose of 9.5 Gy. Mononuclear leukocytes (1  106
cells) were injected through the tail vein of recipient mice.
After one month, successful engraftment in these animals
was confirmed by flow cytometry analysis of their peripheral
blood. About 90% of peripheral blood cells of recipient
mice were reconstituted by GFP cells and considered as
GFP chimera mice for subsequent ischemic experiment.
We induced hind limb ischemia to the recipient mice
(GFP chimera mice) as before. After that mice were
randomly assigned to two experimental groups; Control
(gelatin hydrogel microspheres only), sustained release
form of PRP (100 L platelet-rich plasma/10 mg gelatin
hydrogel micropheres, PRP-sr) and treated for three days.
Fluorescence-activated cell sorting (FACS). Peri-
pheral blood was collected from the GFP chimeric mice
before sacrifice. Then collected blood was pre-treated with
anti-CD34 monoclonal antibody (Hycult Biotechnology,
PB Uden, The Netherlands), followed by rhodamine-con-
jugated secondary antibody (Sigma, Tokyo, Japan). The
percentage of GFP cells and CD34 cells were finally
analyzed from the dot plots by setting appropriate gates in
the fluorescence activated cell sorting on FACStar flow
ctytometer (Becton Dickinson, Tokyo, Japan).
Histological assessment of GFP chimeric mice.
GFP chimeric mice were sacrificed after three days of
treatment and tissue sampling was performed as before.
Cryostat sections (5 m thick) of the tissues were stained
with anti CD34 monoclonal antibody (Hycult Biotech-
nology) followed by rhodamine-conjugated secondary an-
tibody (Sigma).The number of cells both expressing GFP
and reacting with anti-CD34was counted in a blind fashion
(cells/mm2) as before.
Statistical analysis. Results were expressed as the
mean  standard deviation. Differences among groups
were determined by one-way analysis of variance followed
by multiple comparisons using the Bonferroni/Dunn’s test
for more than two groups. Two-tail unpaired student t testwas used to check the significance difference between two
groups. All statistical analyses were performed using the
Statview software (Abacus, Grand Rapids, Mich). A P value
of less than .05 was considered significant.
RESULTS
Concentration of platelets in PRP. Fig 1A shows the
platelet concentration in PRP compared with PPP. The
number of platelets was higher in group PRP than that in
PPP; 517  72  104 vs 0.4  0.14  104 for the groups
PRP and PPP respectively, P  .05.
Concentration of different growth factors in PRP
and PPP. Fig 1 shows the concentration of various
growth factors. The concentrations (pg/mL) of SDF-1
(10,121  892 vs 1,505  49), PDGF-BB (49,080 
4,958 vs 955  109), VEGF (64  7 vs 24  3), bFGF
(43  20 vs 14  2), IGF-1 (7,581 588 vs 2,709 
103 were significantly higher in group PRP than those in
group PPP respectively, P  .05.
In vitro endothelial cell proliferation assay. Figs 2A
and 2B show the dose response and time course of endo-
thelial cell proliferation by PRP. Endothelial cell prolifera-
tion was induced consistently with PRP from day one
through day three. At day three, the numbers of endothelial
cells were higher in groups 10 L of PRP and 100 L of
PRP than those in other groups (1.98  0.69  104,
2.53  0.30  104, 8.84  1.8  104, 14.85  1.56 for
groups C, 1L of PRP, 10L of PRP, and 100L of PRP,
respectively; P  .05). Although there is significant differ-
ence in endothelial cell proliferation between groups 10 L
of PRP and 100 L of PRP, 10 L PRP shows almost
confluent at day three.
In vitro matrigel capillary tube formation assay.
Figs 2C and 2D show the capillary tube formation by PRP.
Capillary tube area was higher as detected in per m2 area
(92,326  7,808, 39,978  8,522 for groups PRP and
control respectively, P  .05).
Blood perfusion. The time course of blood perfusion
(LDPII) is depicted in Fig 3. The LDPII in groups PRP-sol
and PRP-sr was significantly higher than that in the other
groups four weeks after treatment (57 12, 56 9, 72
7, 98  4 for groups C, PPP, PRP-sol, and PRP-sr,
respectively; P  .05). The LDPII in group PRP-sr was
higher than that in group PRP-sol. No significant differ-
ence in the LDPII was observed between the groups C and
PPP.
Vascular density. Vascular density and representative
photomicrographs of histological sections are shown in Fig
4, C and D, respectively. Vascular density (4A) in the
groups PRP-sol and PRP-sr was higher than that in the
other groups at four weeks after initiation of treatment
(151  16, 158  12, 189  39, 276  39 for groups C,
PPP, PRP-sol, and PRP-sr, respectively; P  .05). The
vascular density in group PRP-sr was higher than that in
group PRP-sol. No significant difference in the vascular
density was observed between the groups C and PPP.
Mature vessel density. Mature vessel density and rep-
resentative photomicrographs of histological sections are
s gro
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density in the groups PRP-sol and PRP-sr was higher than
that in the other groups at four weeks after initiation of
treatment (28 2, 31 3, 52 10, 85 13 for groups C,
PPP, PRP-sol, and PRP-sr, respectively; P  .05). The
mature vessel density in group PRP-sr was higher than that
in the group PRP-sol. No significant difference in the
mature vessel density was observed between the groups C
and PPP.
Effects of sustained release form of PRP on mobi-
lization and homing of CD34 cells in local ischemic
site of GFP chimeric mice. Representative photomicro-
graphs of histological sections and data (graphs) are shown
in Fig 5. At the ischemic calf muscle, the number of CD34
cell in group PRP-sr was significantly higher than that in the
group control after three days of treatment (6  3 vs 18 
5 /mm2 for groups control and PRP-sr respectively). In the
peripheral blood of GFP chimeric mice after three days of
treatment, although there was tendency to increase, there
was no significant difference in the number of CD34 cells
in peripheral blood between the group PRP-sr and that of
Fig 1. Platelet-rich plasma (PRP) contains a large num
platelet-poor plasma (PPP). (A) Shows the concentration
PPP. (B-F) Represents the concentration of different g
platelet-rich plasma (PRP); stromal cell derived factor (S
n 5; C), Vascular endothelial growth factor (VEGF, n
insulin like growth factor (IGF-1, n  5; F). *P  .05 vthe control group.DISCUSSION
Key findings. This study has shown the efficacy of
sustained release of PRP in therapeutic neovascularization
and this potentiation is triggered by stimulation of angio-
genesis, arteriogenesis, and vasculogenesis in mouse hind
limb ischemia.
Therapeutic angiogenesis. Clinically useful strategies
for enhancing therapeutic angiogenesis have largely been
unrealized. This is likely because stimulation of revascular-
ization involves multiple complex events such as angiogen-
esis, arteriogenesis, and vasculogenesis. These mechanisms
are tightly controlled by growth factors that favor vessel
growth. Single growth factor has limitation to induce op-
timal angiogenesis. The establishment of stable and func-
tional blood vessel networks requires several angiogenic
factors.1-5
PRP contains various growth factors including
SDF-1. It has been reported that PRP is a storage vehicle
for various growth factors such as PDGF, IGF-1, VEGF,
bFGF, TGF-	, etc.7,8 We have measured different growth
f platelets in a small volume of plasma compared with
atelets in the PPP and that in the PRP. *P .05 vs group
factors in platelet-poor plasma (PPP) and that in the
, n 5; B), Platelet derived growth factor (PDGF-BB,
), basic fibroblast growth factor (bFGF, n 6; E), and
up PPP.ber o
of Pl
rowth
DF-1
 5;Dfactors in PRP and have found that PRP contains relatively
group
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amount of VEGF, bFGF compared with PPP (Fig 1).19
PRP containing angiogenic growth factors affects angio-
genesis as well as wound healing.8-11 Platelet-derived mi-
croparticles stimulate proliferation, survival, adhesion, and
chemotaxis of hematopoietic cells in vitro.18 Our findings
are in partial agreement with previous studies and reflect
that PRP is capable of proliferation of endothelial cells and
also can produce endothelial capillary tube. We reasoned,
therefore, that PRP may represent therapeutic intervention
that stimulates ischemic angiogenesis with high efficacy by
virtue of providing various potential angiogenic growth
factors in the mouse hind limb ischemia.
Control release of growth factors in PRP. It has
been recognized that platelets in PRP secrete various growth
factors during the degranulation of  granules and that the
secreted factors exhibit various biologic activities. It is well
known that collagen and thrombin trigger platelet aggrega-
tion and subsequent secretion of platelet growth factors.11
Gelatin, a derivative of collagen, can also trigger the platelet
activation for growth factor secretion, which is similar to that
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Fig 2. Platelet-rich plasma (PRP) induces endothelia
response of PRP on endothelial cell proliferation; n 3
L 101 L of PRP, 100 L 100 L of PRP, n 3 in
resulted by control (C) and PRP (10 L). (C)Capillary t
(D-E) Photomicrographs of capillary tube by control (0
group C, †P  .05 vs group 1 L of PRP, ‡P  .05 vsof thrombin.13 Our previous studies have shown that whenplatelets in PRP are activated with gelatin molecules during
the process of PRP impregnation, growth factors are released
from thePRP.The growth factors secreted are immobilized in
the hydrogel through physicochemical interaction with gela-
tin molecules. The immobilized growth factors are released
from the hydrogel as a result of hydrogel degradation.13,14
Thus,we have used gelatin hydrogel as a carrier for the growth
factors in the PRP.
PRP effect on angiogenesis and arteriogenesis.
Successful reperfusion of ischemic tissue depends not only
on stimulation of angiogenic activity but also on arterio-
genesis. Different growth factors in PRP have different
roles in angiogenesis and restoration of blood flow follow-
ing ischemia.6,20-22 VEGF is the principle stimulatory fac-
tors of angiogenesis after ischemia.23 However, VEGF by
itself promotes the formation of leaky, unstable capillaries
rather than arteriogenesis.5 Neovascularization is a com-
plex event, and interplay between cells and angiogenic
growth factors are necessary for that to occur. For example,
endothelial cell, whether preexisting or progenitor, smooth
muscle cells, and pericytes are required to form complete
E
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angiogenesis. VEGF also promotes mural cell accumula-
tion, presumably through the release of PDGF-BB. Basic
FGF and PDGF are chemoattractants to smooth muscle
cells. Those are also causes of growth of smoothmuscle cell as
well as enlargement of vessel (formation of mature vessels or
arteriogenesis). VEGF recruits hematopoitic stem cells to
ischemic site from bone marrow via circulation. These stem
cells produce capillary plexuses and eventually form mature
vessels. All of these together cause genesis of new vessels for
vascular supply in ischemic limbs.6 So, co-administration of
different growth factors may result in well organized neovas-
cularization useful for therapeutic application.5,24,25
Our laboratory has been doing extensive research using
basic FGF related to neovascularization over the last several
years and has found that bFGF has both angiogenic and
arteriogenic effects.15-17,26 PDGF-BB and its receptor
PDGFR-beta are essential for vascular stabilization by re-
cruitment of mesenchymal progenitors. Lack of PDGF
leads to fragile neovasculature.27 So it is obvious that
PDGF-BB has strong arteriogenic effect after ischemia.
Administration of IGF-1 stimulates angiogenesis and myo-
genesis, although the pro-angiogenic activity appears less
Fig 3. (A) Time course of ischemic/non-ischemic bloo
treatments. (B) Ischemic/non-ischemic blood perfusio
treatments. (C) Blood perfusion ratio in contralateral
treatment of PRP-sr. Group C  Control, group PPP 
sol  treatment with solution form of 100 L platelet-r
form of 100 L platelet-rich plasma; n 10 in each grou
group PRP-sol. NS  no significant difference for grouppotent than that of other angiogenic factors.28 FinallySDF-1 has direct or indirect (via certain secondary cyto-
kines) effects on endogenous angiogenesis.29
There is also cross talk between VEGF and bFGF;
bFGF and PDGF-BB to induce angiogenesis after isch-
emia.5,24,25,30 Our findings have shown that PRP effec-
tively restores blood flow by significant augmentation of
the number of capillaries (angiogenesis) as well as mature
vessels (arteriogenesis) in the mouse hind limb ischemia,
which was confirmed by double staining with endothelial
marker and pericytes marker respectively (Fig 4B). Besides,
sustained release form of PRP showed the highest effect
compared with solution form. Sustained release form of
PRP showed the faster restoration of blood flow (about
90%) within the first two weeks of treatment and consis-
tently increased the flow until full restoration (about
100%). In contrast, solution form of PRP showed relatively
slower perfusion the first two weeks and thereafter a fall of
blood perfusion (Fig 3). Although in this study we could
not recognize the individual role of growth factors and
signaling mechanism of angiogenesis related to PRP, some
authors suggested that PRP acts by concert action of dif-
ferent growth factors in vitro angiogenesis and in post
ischemic tissues. They also supported that stimulation of
fusion ratio in the different groups of mice with various
io in the different groups at four weeks after various
chemic hind limb pre-treatment and four weeks after
atment with 100 L platelet-poor plasma, group PRP-
asma, group PRP-sr  treatment with sustained-release
 .05 vs group C, †P .05 vs group PPP. ‡P .05 vs
-treatment and post-treatment with PRP-sr.d per
n rat
nonis
tre
ich pl
p. *PPRP on angiogenesis is regulated by activation of P13
P. ‡P
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vitro model but it can also be exerted in vivo as well.31
Effect of PRP on vasculogenesis. Vasculogenesis is
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in each group. *P .05 vs group C, †P .05 vs group PPone of the predictor mechanisms for neovascularization,which regards to the recruitment of bone marrow derived
endothelial progenitor cells to the stimulated site.32 Some
laboratories have proposed that bone marrow progenitors
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Volume 50, Number 4 Bir et al 877aged vessels in ischemic tissue. It is already reported that
endothelial progenitor cell recruitment and homing are
guided by SDF-1 and VEGF. Asahara and colleagues have
shown that VEGF contributes to postnatal neovasculariza-
tion by mobilizing bone marrow-derived endothelial pro-
genitor cells.33 SDF-1 regulates the mobilization and local
trafficking of progenitor cells to the ischemic site. De Falco
and colleagues have suggested that transient establishment
of SDF-1 favors stem cell translocation into ischemic tissue,
thereby enhancing neovasculorization.34-36 Our data re-
flects that PRP contains a small amount of VEGF and
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Fig 5. CD34 cells in the peripheral blood and in the
panel: peripheral blood CD34 cells detected by FAC
stained with anti-mouse CD34 antibody. Lower pan
muscles stained with the anti- mouse CD34 antibody.
middle column: CD34 positive cells; right Column:
treatment with sustained-release form of 100 L plate
*P  .05 vs group C.relatively large amount of SDF-1. Our data has also shownthat sustained release of PRP accelerates the homing of
hematopoietic progenitor cells to the ischemic site in vivo,
which reflects the contribution of sustained release of PRP
on vasculogesis in hind limb ischemia. Therefore, SDF-1
and VEGF might contribute to the vasculogenesis effect of
PRP.
Study limitations. Although it is tempting to specu-
late, we are short of establishing: 1) Effect of individual
growth factor related to PRP neovascularization; 2) Dose
response of PRP to angiogeneic effect; 3) signaling path-
way for the angiogenesis related to PRP in vivo; and 4)
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mic calf muscles at three days after surgery. Upper left
per right panel: CD34 cells in ischemic calf muscles
epresentative photomicrographs of the ischemic calf
bars indicate 100 m. Left column: GFP positive cell;
ocated cells. Group C  Control, group PRP-sr 
ich plasma; n  12 in each group. NS: not significant,C
ische
S; up
el: r
Scale
co-l
lets- rother markers for hematopoietic stem cell such as CD133/
JOURNAL OF VASCULAR SURGERY
October 2009878 Bir et alKDR, etc. Further studies are certainly required to investi-
gate the above mentioned limitations.
CONCLUSION
Sustained release of PRP using gelatin hydrogel can be
a highly potent and effective modality for restoring blood
perfusion to mouse hind limb ischemia. This is because
sustained release of PRP stimulates all possible aspects of
vascular remodeling such as angiogenesis, arteriogenesis,
and also vasculogenesis. These may be applicable in the
clinical setting in patients with CLI.
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formation assay, ischemic hind limb, hind limb blood
perfusion, and immunohistological analysis
METHODS
Preparation of gelatin hydrogel microspheres con-
taining PRP. Gelatin hydrogel microspheres incorporat-
ing PRP was prepared as described previously.13-17 Briefly,
Gelatin with an isoelectric point (IEP) of 4.9 was isolated
from bovine bone collegen by an alkaline process using
Ca(OH)2 (Nitta Gelatin, Osaka, Japan). Gelatin micro-
sphere was prepared through cross linking of gelatin in
aqueous solution dispersed in an oil phase. A mixture of the
gelatin aqueous solution (10 wt %, 0.2 mL) and olive oil (5
mL) was preheated to 37° C followed by agitation for one
hour. The emulsion prepared was cooled down in crushed
ice to the allow formation of natural gelatin aqueous solu-
tion. Acetone was then added to the emulsion and stirring
was continued for one hour at 4° C. The resulting micro-
spheres were washed three times with acetone (4° C) and
recovered by centrifugation at 5000 rpm and 4° C for five
minutes. The non cross linked gelatin microspheres (20
mg) were placed in 20 mL of 0.1 wt % Tween-80 aqueous
solution containing 0.13 wt % of glutaraldehyde and stirred
at 4° C for 24 hours to facilitate cross linking. Following
collection by centrifugation (5000 rpm, 4° C, 5 minutes),
the microspheres were agitated in 20 mL of 10 mM aque-
ous glycine solution at 37° C for one hour to block the
residual aldehyde groups on non-reacted glutaraldehyde.
The resulting microspheres were finally washed three times
with double distilled water by centrifugation and freeze
dried. Microsphere diameter was measured for at least 100
microspheres by viewing with a light microscope to calcu-
late their volume. The average diameter of the freeze-dried
microspheres was 26 m.
PRP and PPP were incorporated into the gelatin mi-
crospheres by dropping 100 L of PRP or 100 L of PPP
solution into 10 mg of freeze-dried gelatin microspheres
respectively, which were then left in incubator for one hour
at 370 C. The solution (100 L) was completely absorbed
into the microspheres during swelling, since the solution
volume was less than that theoretically required for the
equilibrated swelling of microspheres. At use, the PRP-
containing gelatin hydrogel microspheres were dispersed in
100 L of PBS, aspirated into 1 mL syringe attached with
a 27-gauze needle (Terumo, Tokyo, Japan), and applied by
single intra-muscular injection to the ischemic site.
Endothelial cell proliferation assay. Mouse MSS31
endothelial cells were kind gift from one of our co-authors
(KY). MSS31 cells were cultured on -MEM medium
supplemented with 10% fetal bovine serum (FBS) and
antibiotics (Nacalai Tesque Inc, Kyoto, Japan). Cultures
were maintained at 370C, 5% CO2, and 100% humidity.
The endothelial cell proliferation assay was performed
as follows; endothelial cells were plated in human plasma
fibronectin coated 24 well culture plates at a density of 3
104 cells/well in -MEM medium containing 10% fetalbovine serum and cultured at 370 C. The next day, medium
was changed to -MEM medium containing 0.5% fetal
bovine serum with or without PRP and culture was contin-
ued for three days. Cells were detached with trypsin, and
the cells were counted using a hemocytometer.18
Tube formation assay. Growth factors reduced matri-
gel (BD Biosciences) was used to coat the wells of 24-well
plates (0.20 mL per well) and was left to polymerize at 370C
for 30minutes.MSS31 endothelial cell suspended in-MEM
medium supplemented only with 0.5% FBS and antibiotics
were added to each well after polymerization. Then PRP was
added to the selectedwell and incubated for six to eight hours.
Medium was removed and the cells were fixed with 4% para-
formaldehyde. Photographswere taken through amicroscope
(Olympus, Tokyo, Japan). Capillary tube area was quantified
using image analysis software (Image J Corporation; National
Institutes of Health, Bethesda, Md).18
Mouse ischemic hind limb model. Hind limb isch-
emia was created in the six-week-old male wild-type mice as
described previously.15,16 Briefly, after the mice were anes-
thetized by an intraperitoneal sodium pentobarbital (60
mg/kg), the entire right saphenous artery and vein, right
external iliac artery and vein, and deep femoral and circum-
flex arteries and veins were ligated, cut, and excised to
obtain a mouse model of severe hind limb ischemia as
described previously.
After surgery, the mice were randomly assigned to four
experimental groups (n  10, each group) and treated for
four weeks: 10 mg gelatin hydrogel microspheres only
(group C); sustained release form of PPP (100 L platelet-
poor plasma/10 mg gelatin hydrogel micropheres, group
PPP), 100 L solution form of PRP (group PRP-sol),
sustained release form of PRP (100 L PRP/10mg gelatin
hydrogel micropheres, group PRP-sr), applied by single
intramuscular injection to the ischemic site.
At four weeks after the initiation of treatment, the mice
were re-anesthetized by an intraperitoneal injection of pen-
tobarbital (60 mg/kg), subjected to the measurements
described below, and then sacrificed with an overdose of
pentobarbital for histological examination.
Measurement of hind limb blood perfusion. The
Hind limb blood perfusion was scanned using a laser Dopp-
ler perfusion image (LDPI) analyzer (Moor Instruments,
Devon, UK) on the first day of treatment and then every
seven days during the whole study period. To eliminate the
influence of the surgical procedure, the average blood
perfusion of the bilateral feet was evaluated. To minimize
influential variables including ambient light and tempera-
ture, perfusion was expressed as the ratio of the blood
perfusion in the right (ischemic) limb to that in the left
(non-ischemic) limb of the same mouse (ie, in terms of the
LDPI index [LDPII]).15,16
Immunohistological analysis. The immunohisto-
logical study was done as described previously.15,16
Briefly, the mice were euthanized and perfusion-fixed
with 4% paraformaldehyde four weeks after the initiation
of treatment. The ischemic calf muscles were embedded
in OCT compound (Sakura Finetechnical, Tokyo, Ja-
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thick) of the tissues were stained with rabbit polyclonal
anti-human von Willebrand factor (vWF) antibody or
mouse monoclonal anti-human smooth muscle actin
(SMA) antibody. As the negative control, rabbit normal
immunoglobulin fraction (Dako Japan, Kyoto, Japan)
was used to show antibody specificity. From each mouse,
eight random fields on two different sections (approxi-mately 3 mm apart) were photographed with a digital
camera (Olympus, Tokyo, Japan). The number of vWF
(endothelial marker)-positive or SMA (vascular smooth
muscle marker)-positive vessels was counted manually in
a blind fashion (vessels/mm2). Vascular density (angio-
genesis) was determined by the counted number of
vWF-positive vessels and mature vessel density (arterio-
genesis) by the counted number of SMA positive vessels.
